
David Fleischer, MD, discusses how the VITESSE trial positions the VIASKIN peanut patch as a promising option for children with peanut allergy.

David Fleischer, MD, professor of pediatrics at Children’s Hospital Colorado and global principal investigator of the VITESSE study.

David Fleischer, MD, discusses how the VITESSE trial positions the VIASKIN peanut patch as a promising option for children with peanut allergy.

According to Fleischer, epicutaneous immunotherapy represents a “marathon, not a sprint,” with potential long-term benefits when started young.

David Fleischer, MD, says phase 3 VITESSE results show the Viaskin peanut patch offers a safe, practical desensitization option for young children with peanut allergy.

February 28th 2026